0.200
0.000
(0.00%)
Jun 19 - Close
CNSX
real-time data -
Disclaimer
Currency in CAD
| Range | 0.20 - 0.20 |
| 52 week | 0.14 - 0.29 |
| Open | 0.20 |
| Vol. | 3,000.00 |
| Mkt cap | 15.89M |
| P/E | - |
| Div/yield | - |
| EPS | -0.04 |
| Shares | 79.45M |
| Beta | - |
| Inst. own | - |
Key stats and ratios
| Q3 (Sep '12) | 2011 | |
| Net profit margin | -4092.63% | - |
| Operating margin | -4092.68% | - |
| EBITD margin | - | - |
| Return on average assets | -136.54% | -145.12% |
| Return on average equity | -239.09% | -155.46% |
| Carbon Disclosure Rating | - | - |
Address
Unit 10, 81 Zenway Blvd
WOODBRIDGE, ON L4H 0S5
Canada
+1-905-8569797 (Phone)
+1-905-8562177 (Fax)
WOODBRIDGE, ON L4H 0S5
Canada
+1-905-8569797 (Phone)
+1-905-8562177 (Fax)
Website links
External links
Advertisement
Description
Pivotal Therapeutics, Inc. is a Canada-based pharmaceutical company with a focus on cardiovascular health. The Company offers VASCAZENTM, is a prescription grade, ultra-pure Omega 3 fatty acid for the dietary management of cardiovascular disease in patients manifesting an Omega 3 fatty acid deficiency. VASCAZENTM is manufactured according to FDA (Food and Drug Administration) current Good Manufacturing Practices (cGMP) and each capsule of VASCAZENTM provides 680 mg of Eicosapentaenoic (EPA) and 110 mg of Eicosapentaenoic (EPA), for oral administration.
Officers and directors
| George Jackowski Ph.D. | Chairman of the Board, Chief Scientific Officer | |
| Rachelle MacSweeney | President, Director | |
| Eugenio Bortoluzzi | Chief Executive Officer, Chief Financial Officer, Director | |
| James J. Carey | Independent Director | |
| John S Gebhardt | Independent Director | |
| Giuseppe Simeone | Independent Director |